Pirtobrutinib
Pirtobrutinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Mantle Cell Lymphoma、Chronic Lymphocytic Leukemia、Small Lymphocytic Lymphoma、Waldenstrom Macroglobulinemia。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
23 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- H. Lee Moffitt Cancer Center and Research Institute
- BeOne Medicines
- Memorial Sloan Kettering Cancer Center
- M.D. Anderson Cancer Center
- Peter MacCallum Cancer Centre, Australia
- Eli Lilly and Company
- Zhejiang Cancer Hospital
- The First Affiliated Hospital of Soochow University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、澳大利亚、奥地利、比利时、加拿大、中国、Croatia、Czechia、法国、Hungary、爱尔兰、Israel
正在招募患者的 Pirtobrutinib 研究
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
II 期招募中美国NCT06263491Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
II 期招募中澳大利亚NCT06812715A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
IV 期招募中美国澳大利亚奥地利比利时NCT07218341Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
II 期招募中美国NCT06553872Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
II 期招募中中国NCT07416890Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
II 期招募中中国NCT07255963Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
II 期招募中Portugal西班牙NCT07285590Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
I 期招募中美国澳大利亚NCT03666000A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
IV 期招募中美国澳大利亚法国意大利NCT06876649A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
I 期 / II 期招募中美国中国丹麦法国NCT06721013Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
II 期招募中美国NCT06948786Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
不适用招募中美国NCT05643235A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
II 期招募中美国澳大利亚比利时加拿大NCT06588478Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
II 期招募中美国NCT05536349Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
II 期招募中美国NCT06043674AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
I 期招募中美国NCT05602363Mosunetuzumab for CLL MRD Clearance
I 期 / II 期招募中美国NCT07052695A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
IV 期招募中美国澳大利亚法国意大利NCT06876662Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
II 期招募中美国NCT06967610Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
II 期招募中美国NCT06390956A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
II 期招募中澳大利亚NCT05833763ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
III 期招募中美国NCT07342478A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
II 期招募中中国NCT07350850Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
III 期招募中美国NCT07516093
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。